Erika Yan Wang

Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Enteric pathogens are a major contributor to the global disease burden, necessitating vaccines capable of inducing robust gastrointestinal mucosal immunity.

Abstract Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold tremendous promise for in vitro modeling to assess native myocardial function and disease mechanisms, as well as testing drug safety and efficacy. However, current hiPSC-CMs are functionally immature, resembling in vivo CMs of fetal or neonatal developmental states. The use of targeted culture media and organoid formats have been identified as potential high-yield contributors to improve CM maturation.

How much tissue maturation is enough to capture key physiological responses in OOAC? How many cell types should we add to the OOAC to faithfully recapitulate the organ function? Where in the drug development pipeline should OOAC devices be placed: before animal studies, in parallel to animal studies, or completely replace animal studies? What is needed to be able to replace human clinical trials (i.e., run the trial on a chip instead of with human volunteers)?